Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?. (24th June 2019)

• Record Type: Journal Article
• Authors: Ramacciotti, Eduardo; Agati, Leandro B.; Caffaro, Roberto Augusto; Volpiani, Giuliano G.; Lopes, Renato D.; Comerota, Anthony J.; Fareed, Jawed
• Is Part Of: Clinical and applied thrombosis/hemostasis. Volume 25(2019)
• Publication Date: 2019-06-24
• Subjects: direct oral anticoagulants -- cancer -- venous thromboembolism; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 616.13
• DOI: 10.1177/1076029619856433
• Languages: English
• ISSNs: 1076-0296

Abstract

Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.